Prevalence of new onset erectile dysfunction among Damietta governorate men after contracting COVID-19.

BACKGROUND: Several reports showed that sexual function was affected during and after the COVID-19 pandemic. AIMS: The objective of the study was to demonstrate whether a realistic association exists between the COVID-19 pandemic and erectile dysfunction (ED) among a sampled Egyptian population in Damietta governorate. METHODS: This cross-sectional study consisted of 330 adult males diagnosed with COVID-19 infection. They were categorized in three age groups (18-29, 30-39, and 40-50 years, respectively). COVID-19-confirmed cases were assessed by the Arabic version of the International Index of Erectile Function questionnaire (IIEF) scores. RESULTS: The prevalence of ED according to the IIEF was 55.1%. The ED was categorized into mild ED which represents 25.8% of the patients, mild to moderate which represents 22.4% of the patients, moderate which represents 7% of the patients, and severe which represents 0% of the patients. We found a significant negative correlation between the age of the patients and the IIEF score. Also, we found an association between the severity of COVID-19 infection and the IIEF score. CONCLUSION: An association of new-onset ED in men who suffered COVID-19 infection was established. This may be due to virus-induced endothelial cell dysfunction; however, an underlying mechanism and causation have not yet been clearly elucidated. While it appears that COVID-19 infection may be a risk factor for ED, additional research is needed to establish causality.

Hair disorders associated with post-COVID-19 infection in females: a cross-sectional study.

BACKGROUND: Coronavirus disease (COVID-19) currently named SARS-CoV-2 is a contagious disease caused by a coronavirus. The virus may infect the hair follicles directly or indirectly through systemic changes in the immune or hormonal systems. AIMS: In the current study we aimed to determine the prevalence of hair disorders in females infected with COVID-19. METHODS: Data was collected using a questionnaire covering four main domains: personal data, past medical history, COVID-19 history and treatment, and existence of any hair problems and their management. No identifier or sensitive data were collected. Those complaining of hair loss were subjected to complete general and local hair examination using trichoscopy to confirm hair loss. RESULTS: Hair problems were reported in 307 (61.4%) of COVID-19-infected female subjects. A total of 68.1% patients reported that hair loss existed and increased after COVID-19; 29.6% reported their hair problems only post-COVID-19 while 2.3% had hair shedding issues during infection only. The main reported hair problems were telogen effluvium (60.8%), increased gray hair (13.8%), seborrheic dermatitis (5.6%) trichotillomania (3.6%), and alopecia areata (2.2%). CONCLUSION: In conclusion, we reported prevalence of post-COVID hair fall that was confirmed by trichoscopy and which affected approximately 61.4% of infected females.

Prevalence of female sexual dysfunction among diabetic females: a cross-sectional case controlled study.

BACKGROUND: Sexual relationships, sexual functions are all parts of the female sexual identity and which influence physiological, psychological, and reproductive functions of women. AIM OF THE WORK: The study aimed to identify prevalence of Female Sexual Dysfunction (FSD) in women affected by type 1 and type 2 Diabetes Mellitus (DM) and to evaluate the impact of diabetes on female sexuality. PATIENT AND METHODS: This cross-sectional study was carried out on 400 married females who were interviewed to answer Female Sexual Function Index (FSFI) questionnaire and were divided into two groups: the first group included 300 diabetes patients (134 patients with type 1 DM and 166 patients with type 2 DM), while the second included 100 women not diagnosed with diabetes who served as controls. RESULTS: Considering female sexual dysfunction (score < 26.55), there was statistically significant increase of patients with female sexual dysfunction (FSD) in Type 1 DM (50.7%) when compared to type 2 DM patients (28.9%) or control group (10.0%). CONCLUSION: FSD is a significant health problem in premenopausal women complaining of DM. Females with type 1 DM were more affected than females with type 2 DM, who in turn were more affected than healthy controls. Long duration of the disease was the main risk factor for developing FSD.

Microneedling-assisted topical tranexamic acid solution versus 4% hydroquinone for treating melasma: A split-face randomized study.

BACKGROUND: Melasma, also known as chloasma or mask of pregnancy, is a common, acquired, hyperpigmentary disorder usually affecting females. Tranexamic acid (TA), a derivative of amino acid lysine, has shown promising results over the past few years when used along with other therapies and when used as a stand-alone therapy. AIM OF THE WORK: In this study, we aimed to evaluate and compare the effectiveness of topically applied tranexamic acid after microneedling versus topically applied hydroquinone (HQ) 4% alone in patients with melasma. PATIENTS AND METHODS: Fifty selected patients were divided randomly according to the random number allocation method into two groups (25 patients each) of A (topical 4% hydroquinone, nightly application) and B (microneedling + topical 4% TA, every other week). RESULTS: After eight weeks of treatment, the mean modified MASI score of the HQ treated side changed from 6.604 ± 4.02 to 3.032 ± 1.19 with a mean decrease percentage of 54.8% ± 19.4%. This reduction in modified MASI score was found to be statistically significant, (p < 0.001). MASI score of group B (TA +microneedling) changed from 6.348 ± 3.84 to 3.712 ± 1.19 with mean decrease percentage of 57.4% ± 23.4% which was also statistically significant, (p < 0.001). CONCLUSION: We demonstrated safety and efficacy of both used modalities and with minimal side effects. Topical HQ application achieved minimal non-significant higher satisfactory results among raters and subjects.

Calprotectin in acne vulgaris: A possible contributory role.

BACKGROUND: Acne vulgaris (AV) is a common inflammatory skin disease involving dysfunction of the pilosebaceous unit. Many mechanisms for the pathogenesis of acne have been postulated; however, the precise pathogenesis is still uncertain. AIM: Evaluation of the level of serum calprotectin in patients with AV and its correlation with the different clinical variables of the disease, particularly severity. PATIENTS AND METHODS: This is a case-control study that included ninety subjects who were subdivided into two groups; group I, which included sixty patients complaining of AV with different grades of severity, and group II that included thirty apparent healthy age and sex-matched participants as a control group. Severity of AV was determined according to the Global Acne Grading System (GAGS). Serum calprotectin level was measured in both patients and controls by the enzyme-linked immunosorbent assay (ELISA) method. RESULTS: A highly statistically significant difference in the serum calprotectin level was found between patients with AV and control subjects. A highly significant positive correlation was found between the serum calprotectin levels and the severity of acne. Similarly, a significant positive correlation was found between serum calprotectin levels and the duration of the disease. CONCLUSION: Serum calprotectin levels are increased in acne patients and are positively correlated with its severity.